Emerging therapeutic options for metastatic exocrine pancreatic cancer

Keyphrases

• Adenocarcinoma 33%
• Clinical Benefit 33%
• Clinical Development 33%
• Cytotoxic Agents 33%
• Effective Therapy 33%
• Emerging Therapeutics 100%
• Erlotinib 33%
• Excellent Performance 33%
• Exocrine Pancreas 33%
• Familial Pancreatic Cancer 100%
• Fluorouracil 33%
• FOLFIRINOX 33%
• Gemcitabine 100%
• Gene Therapy 33%
• Investigational Agents 33%
• Median Survival 33%
• Metastatic Disease 66%
• New Standards 33%
• Pancreatic Cancer 33%
• Patient Survival 33%
• Paucity 33%
• Performance Status 33%
• Signal Transduction 33%
• Standard of Care 33%
• Targeted Agents 33%
• Therapeutic Potential 100%
• Therapeutic Vaccine 33%
• Therapy Strategy 33%
• Tumor Microenvironment 33%
• Tumor-related Genes 33%
• Vaccine Therapy 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Adenocarcinoma 33%
• Erlotinib 33%
• Fluorouracil 33%
• Gemcitabine 100%
• Immunotherapy 33%
• Metastasis 66%
• Pancreas Cancer 100%
• Tumor Microenvironment 33%
• Tumor Vaccine 33%